Brief: Pharmaust Says FDA Provided Clear Feedback For ODD Approval

Neurizon Therapeutics

29/01/2024 01:43

Jan 29 (Reuters) - Pharmaust Ltd  PAA.AX :
    * FDA PROVIDES CLEAR FEEDBACK FOR ODD APPROVAL
    * FDA REQUESTED CLINICAL TRIAL DATA TO SUPPORT GRANTING OF
ORPHAN
DRUG DESIGNATION FOR TREATMENT OF MND/ALS 
    * WILL SUBMIT AMENDMENT TO FDA FOLLOWING RELEASE OF PHASE 1
MEND
STUDY CLINICAL DATA THIS QTR

Source text for Eikon:  ID:nASXbMSt3 
Further company coverage:  PAA.AX 

 ((Reuters.Briefs@thomsonreuters.com;))